BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
411.29
-5.25 (-1.26%)
Nov 16, 2026, 4:00 PM EST - Market closed
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of 1.89B CNY in the quarter ending September 30, 2026, with 33.81% growth. This brings the company's total for the last twelve months to 6.61B, up 32.86% year-over-year. In the year 2025, BeOne Medicines AG had annual revenue of 5.34B with 40.23% growth.
Revenue (ttm)
6.61B CNY
Revenue Growth
+32.86%
P/S Ratio
7.29
Revenue / Employee
550,541 CNY
Employees
12,000
Market Cap
46.98B USD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full BeOne Medicines AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | 173.79M | 711.45% |
| Dec 31, 2017 | 24.43M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 16.90B |
| Incyte | 6.01B |
| argenx SE | 5.92B |
| Alnylam Pharmaceuticals | 5.01B |
| Genmab | 4.30B |
| BioNTech SE | 2.75B |
| Royalty Pharma | 2.62B |
| Moderna | 2.53B |
ONC News
- 3 days ago - BeOne Medicines price target raised to $476 from $465 at Morgan Stanley - TheFly
- 10 days ago - BeOne Medicines price target raised to $477 from $454 at TD Cowen - TheFly
- 10 days ago - BeOne Medicines price target raised to $465 from $425 at Morgan Stanley - TheFly
- 10 days ago - BeOne Medicines Q3 Earnings Call Highlights - MarketBeat
- 10 days ago - BeOne Medicines price target raised to $448 from $420 at Truist - TheFly
- 10 days ago - BeOne Medicines price target raised to $463 from $405 at Citizens - TheFly
- 10 days ago - BeOne Medicines price target raised to $446 from $415 at Barclays - TheFly
- 11 days ago - Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics - Nasdaq